Member Info for Laura2022

This is great to see

Totally agree Trench

Perhaps Oliver worth looking at what the company does and the recent contracts (StephenFryUp did a nice summary )

Gluck

Oliver

That cleared over 2mths ago when there was over 10 x the placing shares traded in 2 weeks in late Aiugust

What happened was about 10 people bought and sold for a loss as per the match trades

From VAL board re: VAL201

Jwallows

Strong Buy

$60;000,000 prospectusToday 13:00

Merger is completing any day now. Merger contingent funds will be released to theoremRX and Val will be paid 7 figures.

These are the facts; yesterday, someone took down my post!

Yes, amd if you take away the cash of £750k from the market value then PYC only valued at £1.1mln which is ridiculous given the actual qmd potential revenue s

Well worth reading the September annual report

Outlook

The impact of the Company's strengthened Board is already being felt through the implementation of new marketing activities, collaborations such as with Inaphaea and Beyond Blood and through the proposed expansion of its consulting business into the field of biostatistics. The Company is looking forward to a successful financial year 2024 during which it aims to achieve a new best ever level of total income, generated from its current core business and emerging biostatistics consulting offering

Hello Island PYC and VAL worked together from 2019-2021 on a new prostate treatment, VAL have been awaiting 18tmtjs for their partner to secure NASDAQ funding to then pay VAL and PYC. This funding is expected in the next week or so (see VAL discussion group and recent RNS

Feb 2021 original PYC and VAL deal

Physiomics will receive a fee (capped at £6m) of 6% of any future net revenues that may be received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indication, including prostate cancer, endometriosis and treatment for Coronavirus infection.

Val CEO Q and A October 2023

"We have every indication we will be able to put out a substantial update beofe the end of the year - if that wasn't the case then clearly we would have already announced that wasn't the case.. we have a good degree of certainty."

"When the sublicense is signed, we will then be able to invoice them (TheoremRX) for the time that has been spent under the service agreement.. along with the upfront payments and the early milestone payments"

Thanks Ackers

PY is not only due for another £1mln+of contracted revenues but also access to various funding programmes like Horizon and also up to £6mln in royalties when the VAL 201 drug gets out licence possibly on or around 6th -15th November according to the NASDAQ timings and also re iterated by VAL CEO 6 weeks ago

Yes Acker

I posted the A.I article on BBC..thisis now the 3rd article which mentions CRUK for whom PYC work for (cancer research UK)

Yes Acker

That funding if I remember was Horizon Funding announced by Sunack a few months ago ?

Huge amount amount of funding available and PYC at heart of UK/E.U initiatives

The new appointment made to the PYC company are involved in growing sectors of

》artificial intelligence

》 predictive mathematic modelling

》bio statistics

They raised £390k in June and also had £400k in the bank ,as they are a software company their over heads are low , the £790k is good for the foreseeable future (see Sept 2023 annual report)

The potential £6mln( not all at once ) VAL201 could be nearing a conclusion in next weeks or so (see VAL merger information which triggers the out licence of VAL201 which PYC gain from having done the modelling

The DoseMeRx USA deal potentially integrating PYC dosing tool Into a multi $mln US market

The personalised/A.I capabilities

The £1mln+ pipeline of pre-checked deals /contracts on top of the c £300k+ won since July 2023 (estimates )

The move into bio statistics

All for £1.9mln market value

Island/Acker

£2mlnvalue is ridiculous

Look at OBD...now £50mln cap with àn excellent prostate cancer test, PYC also have one I developed and must more besides

See StephenFryUp summary yesterday

No shares available PYC

From PYC website regarding PYC A.I applications

Personalised Dosing Tool Development

Data Identification

Identified public domain data on treatment of prostate cancer using docetaxel for 400+ patients from the comparator arm of a clinical tria

AI & Machine Learning

Applied AI techniques such as neural networks and other machine learning approaches to identify key factors linking dose, toxicity and efficacy

Web-Based Tool

Developed a web-based tool that could, if approved, form the basis of a decision support system for clinicians treating patients with prostate cancer to help reduce cost of toxicity and improve outcomes for patients

Yes Newuncle

Just posted article on PYC at that is exactly what PYC do

Https://www.bbc.co.uk/news/health-67264350

My point being ...why spend 300 posts over 30 days on just on company finalising funding, while also spreading lies fofo6mths-9mth about an imminent placing at 2p

I just pity them and their family must be proud (doubt they actually know what these grown adults do to get a kick !!)

Pathetic

Yes darkknight

What it proves is that its not a noble crusade against AIM companies , its a twisted vendetta against the company or individuals

So clearly transparent and unedifying

There are so many disastrous AIM shares out there, some suspended,some can't get funding,some whic have led thir share holders a merry dance for years (LVCG DKE BIDS VLS VRS ENET etc)

Yet they target 2 shares trying to defeat cancer (PYC and VAL)

Very odd